{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:18:22Z","timestamp":1790936302619,"version":"4.1.0"},"reference-count":31,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,1]]},"abstract":"<jats:p>Bevacizumab is a human monoclonal immunoglobulin G1 antibody to vascular endothelial growth factor indicated in several adult diseases. Emerging literature and expert opinion support the off-label use of intravitreal bevacizumab in the treatment of retinopathy of prematurity (ROP), a common disease process seen in premature neonates. One of the most common side effects of systemic therapy in adults is hypertension; however, this has not been well described in infants receiving bevacizumab for ROP. In this report, we review a case of a former 25-week premature infant treated for stage 3 ROP with administration of intravitreal bevacizumab. The immediate posttreatment course was uncomplicated; however, at 10 days posttreatment, he developed new-onset systemic hypertension. In addition, neuroimaging revealed new areas of vasogenic edema, which improved over time. To the best of our knowledge and after a review of the literature, neither of these effects has been described in neonates after intravitreal bevacizumab for ROP.<\/jats:p>","DOI":"10.1542\/peds.2019-1814","type":"journal-article","created":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T13:25:19Z","timestamp":1575552319000},"source":"Crossref","is-referenced-by-count":12,"title":["Hypertension and Neuroimaging Changes After Bevacizumab for Retinopathy of Prematurity"],"prefix":"10.1542","volume":"145","author":[{"given":"Grace","family":"Twitty","sequence":"first","affiliation":[{"name":"Departments of Pediatrics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Weiss","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet S.","family":"Albayram","sequence":"additional","affiliation":[{"name":"Radiology, University of Florida, Gainesville, Florida; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keliana","family":"O\u2019Mara","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Florida Health Shands Hospital, Gainesville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith E.","family":"Mowitz","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2020,1,1]]},"reference":[{"issue":"3","key":"2021120913115789400_B1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/20009666.2018.1478563","article-title":"Posterior reversible encephalopathy syndrome (PRES) after bevacizumab therapy for metastatic colorectal cancer","volume":"8","author":"Hamid","year":"2018","journal-title":"J Community Hosp Intern Med Perspect"},{"issue":"5,","key":"2021120913115789400_B2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.seminoncol.2006.08.002","article-title":"Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer","volume":"33","author":"Ellis","year":"2006","journal-title":"Semin Oncol"},{"issue":"4","key":"2021120913115789400_B3","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.clp.2014.08.011","article-title":"Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity","volume":"41","author":"Hartnett","year":"2014","journal-title":"Clin Perinatol"},{"key":"2021120913115789400_B4","unstructured":"Dougherty\u2008M, Wittenborn\u2008J, Phillips\u2008E, Swenor\u2008B. Published examination-based prevalence of major eye disorders.\u20082018. Available at: www.norc.org\/PDFs\/VEHSS\/EyeConditionExamLiteratureReviewVEHSS.pdf. Accessed May 30, 2019"},{"issue":"12","key":"2021120913115789400_B5","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/IAE.0000000000001719","article-title":"The cutting edge of retinopathy of prematurity care: expanding the boundaries of diagnosis and treatment","volume":"37","author":"Yonekawa","year":"2017","journal-title":"Retina"},{"issue":"11","key":"2021120913115789400_B6","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"7","key":"2021120913115789400_B7","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"2021120913115789400_B8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1542\/peds.2012-2996","article-title":"Screening examination of premature infants for retinopathy of prematurity","volume":"131","author":"Fierson","year":"2013","journal-title":"Pediatrics"},{"issue":"7","key":"2021120913115789400_B9","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.ophtha.2011.04.028","article-title":"Retinopathy of prematurity in the time of bevacizumab: incorporating the BEAT-ROP results into clinical practice","volume":"118","author":"Moshfeghi","year":"2011","journal-title":"Ophthalmology"},{"issue":"8","key":"2021120913115789400_B10","doi-asserted-by":"crossref","first-page":"e476","DOI":"10.1542\/neo.13-8-e476","article-title":"Interventions in retinopathy of prematurity","volume":"13","author":"Silva","year":"2012","journal-title":"NeoReviews"},{"issue":"4","key":"2021120913115789400_B11","doi-asserted-by":"crossref","first-page":"e20153218","DOI":"10.1542\/peds.2015-3218","article-title":"Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity","volume":"137","author":"Morin","year":"2016","journal-title":"Pediatrics"},{"issue":"1","key":"2021120913115789400_B12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jaapos.2017.10.006","article-title":"Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity","volume":"22","author":"Kennedy","year":"2018","journal-title":"J AAPOS"},{"issue":"1","key":"2021120913115789400_B13","doi-asserted-by":"crossref","first-page":"e0148019","DOI":"10.1371\/journal.pone.0148019","article-title":"Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment","volume":"11","author":"Lien","year":"2016","journal-title":"PLoS One"},{"key":"2021120913115789400_B14","doi-asserted-by":"crossref","first-page":"xxiii","DOI":"10.1016\/j.ajo.2017.10.027","article-title":"Evolving concepts in the management of retinopathy of prematurity","volume":"186","author":"Sternberg","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"2021120913115789400_B15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/cncr.28972","article-title":"Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway","volume":"121","author":"Hamnvik","year":"2015","journal-title":"Cancer"},{"issue":"2","key":"2021120913115789400_B16","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s10637-010-9549-5","article-title":"Treatment of bevacizumab-induced hypertension by amlodipine","volume":"30","author":"Mir","year":"2012","journal-title":"Invest New Drugs"},{"issue":"3","key":"2021120913115789400_B17","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/11590180-000000000-00000","article-title":"Bevacizumab-induced hypertension: pathogenesis and management","volume":"25","author":"Syrigos","year":"2011","journal-title":"BioDrugs"},{"issue":"3","key":"2021120913115789400_B18","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.ygyno.2017.09.017","article-title":"Genetic predisposition to bevacizumab-induced hypertension","volume":"147","author":"Frey","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"5","key":"2021120913115789400_B19","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.cjca.2014.02.011","article-title":"Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome","volume":"30","author":"Small","year":"2014","journal-title":"Can J Cardiol"},{"issue":"8","key":"2021120913115789400_B20","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1038\/eye.2008.360","article-title":"The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension","volume":"23","author":"Rasier","year":"2009","journal-title":"Eye (Lond)"},{"issue":"7","key":"2021120913115789400_B21","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1634\/theoncologist.2014-0149","article-title":"Posterior reversible encephalopathy syndrome in patients with cancer","volume":"20","author":"Singer","year":"2015","journal-title":"Oncologist"},{"issue":"7","key":"2021120913115789400_B22","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.3174\/ajnr.A1588","article-title":"Hemorrhage in posterior reversible encephalopathy syndrome: imaging and clinical features","volume":"30","author":"Hefzy","year":"2009","journal-title":"AJNR Am J Neuroradiol"},{"issue":"8","key":"2021120913115789400_B23","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1007\/s00415-016-8377-8","article-title":"Posterior reversible encephalopathy syndrome","volume":"264","author":"Fischer","year":"2017","journal-title":"J Neurol"},{"key":"2021120913115789400_B24","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jns.2019.07.018","article-title":"Posterior reversible encephalopathy syndrome: a review with emphasis on neuroimaging characteristics","volume":"404","author":"Tetsuka","year":"2019","journal-title":"J Neurol Sci"},{"key":"2021120913115789400_B25","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/B978-0-7020-4088-7.00109-7","article-title":"Posterior reversible encephalopathy syndrome","volume":"121","author":"Lamy","year":"2014","journal-title":"Handb Clin Neurol"},{"key":"2021120913115789400_B26","doi-asserted-by":"crossref","first-page":"bcr2012007995","DOI":"10.1136\/bcr-2012-007995","article-title":"Posterior reversible encephalopathy syndrome after bevacizumab therapy in a normotensive patient","volume":"2013","author":"Abbas","year":"2013","journal-title":"BMJ Case Rep"},{"key":"2021120913115789400_B27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jocn.2017.01.005","article-title":"Posterior reversible encephalopathy syndrome (PRES) with sub-arachnoid haemorrhage after bevacizumab and 5-FU","volume":"40","author":"Massey","year":"2017","journal-title":"J Clin Neurosci"},{"issue":"3","key":"2021120913115789400_B28","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1089\/jop.2009.0148","article-title":"Posterior reversible encephalopathy syndrome after intravitreal bevacizumab injection in patient with choroidal neovascular membrane secondary to age-related maculopathy","volume":"26","author":"Artunay","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"issue":"3","key":"2021120913115789400_B29","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ejrad.2006.12.001","article-title":"Widening the spectrum of PRES: series from a tertiary care center","volume":"62","author":"Gocmen","year":"2007","journal-title":"Eur J Radiol"},{"issue":"4","key":"2021120913115789400_B30","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1055\/s-0030-1249031","article-title":"Posterior reversible encephalopathy syndrome in early infancy","volume":"222","author":"Kummer","year":"2010","journal-title":"Klin Padiatr"},{"issue":"5","key":"2021120913115789400_B31","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.pediatrneurol.2013.06.020","article-title":"Posterior reversible encephalopathy syndrome in an infant","volume":"49","author":"Mrelashvili","year":"2013","journal-title":"Pediatr Neurol"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2019-1814\/1078604\/peds_20191814.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2019-1814\/1078604\/peds_20191814.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T03:42:24Z","timestamp":1639107744000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/145\/1\/e20191814\/36998\/Hypertension-and-Neuroimaging-Changes-After"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,1]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1,1]]},"published-print":{"date-parts":[[2020,1,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2019-1814","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,1]]},"article-number":"e20191814"}}